5th annual meeting of the
Arbeitsgruppe „Experimentelle Allergologie“ der ADF (AGEA)
Date: Thursday, 13th March 2013
Time: 9:00-12.45
Seminarraum S 63, Philosophikum,
Universitätsstr. 41, Köln

PROGRAM

9.00-9.20 Election new AG speaker/deputy speaker, discussion „Vereinsgründung einer AG innerhalb der ADF“

9:20 – 09:45 Mareike Wegner, Allergy Research Group, Department of Dermatology, University Freiburg Medical Center, Freiburg, Germany
MPI-2 cells, a new model for tissue type macrophages

09:45 – 10:10 Christian Möbs, Department of Dermatology and Allergology, Philipps University Marburg, Germany
The ELIFAB assay: a new tool to characterize the blocking antibody activity in patients with hymenoptera venom allergy

10:10 – 10:35 Kai Hänel, Department of Dermatology and Institute of Biochemistry and Molecular Biology, RWTH Aachen, Germany
Bifunctional role of IL-31 in skin biology

10:35 – 11:00 Jan Gutermuth, Center of Allergy and Environment (ZAUM), Technical University and Helmholtz Center Munich, Munich, Germany
Intranasal exposure to ragweed pollen extract leads to rapid allergic sensitization with adenosine acting as adjuvant factor

11.00 - 11.10 Short Break

11.10 – 11.35 Anja Rabenhorst, Department of Dermatology, University of Cologne, Cologne, Germany
Novel insights into mastocytosis-associated osteoporosis: Mast cells in indolent systemic mastocytosis produce bone cytokines

11.35 – 12.00 Isabelle Beck, ZAUM – Center for Allergy & Environment, Technische Universität and Helmholtz Zentrum München, Munich, Germany
Effects of pollen-derived non-protein substances on the allergic immune response in vivo: roles of adenosine, PALMs and neuroreceptors
12.00 – 12:25 **Anja Preuhsler**, Allergy Research Group, University Medical Center, University of Freiburg, Germany  
**Allergen specific tolerance induction is independent of interleukin 10 signaling in T cells, B cells or neutrophils/monocytes.**

12.25 – 12:50 **Janine Gericke**, Dpt. of Dermatology and Allergy, Allergie-Centrum-Charité, Berlin, Germany  
**Omalizumab does not inhibit mast cell and basophil activation in vitro**

**Oral presentations:** 20 minutes for presentation + 5 minutes for discussion, language: English